TECH
TECH
TECH
TECH NASDAQ
Bio-Techne is noted in the headline 'CMB.TECH: Q2 Was Strong, But Valuation Looks Full (Downgrade)'. The company holds a market capitalization of $11.30B, supported by full-year revenue of $1.22B and a TTM EPS of 1.17. Its current valuation is highlighted by a PE ratio of 61.69 alongside an FCF yield of 2.33%.
Based on seekingalpha.comCMB.TECH: Q2 Was Strong, But Valuation Looks Full (Downgrade)
CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript
CMB.TECH Q2 Earnings Call Highlights
CMB.TECH ANNOUNCES Q2 2026 RESULTS
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Stonks with professional market data, charts beside chat, and your portfolio context.
Tape shows delayed public market data. Not investment advice.